This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of ALKS 2680 (Alixorexton) in adults with narcolepsy type 1. Approximately 150 participants will be assigned to receive one of two doses of ALKS 2680 or placebo for 12 weeks. The study is designed to assess improvements in daytime wakefulness, cataplexy frequency, and overall disease severity using objective sleep testing and patient-reported outcome measures. If interested in participating in this clinical study contact the Director, Clinical Trial Manager at +1-888-235-8008 (US Only) / 571-599-2702 (Global) or by email at clinicaltrials@alkermes.com.

This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of ALKS 2680 (Alixorexton) in adults with narcolepsy type 2. Participants are assigned to one of three dose levels of ALKS 2680 or placebo for 12 weeks, with the primary goal of measuring improvements in daytime wakefulness (using the Maintenance of Wakefulness Test) compared with placebo. Secondary outcomes assess sleepiness, fatigue, cognitive function, and overall clinical improvement, along with safety and tolerability. Interested in participating in this study contact the Director Clinical Trial Manager at +1-888-235-8008 (US Only) or 571-599-2702 (Global), or by email at clinicaltrials@alkermes.com.

This is a Phase 3 clinical trial testing TAK‑861, a new drug for narcolepsy type 1 (with cataplexy). The main goal is to see whether the drug’s benefits are maintained or lost when it is stopped, while also evaluating its safety. If interested in participating contact Takeda at +1-877-825-3327 or by email at medinfoUS@takeda.com.

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). Interested in participating contact Orexin Centessa Program Lead at 617-468-5770 or by email at ORX750-LTE@centessa.com.

Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. If interested in participating contact the Takeda Team at +1-877-825-3327 or by email at medinfoUS@takeda.com.

The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1. For more information contact Miran Cho at 650-724-4149 or by email at mirancho@stanford.edu or Mila Trabanino at milaludi@stanford.edu.

A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects with Idiopathic Hypersomnia (Vibrance-3) The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH) The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Contact Takeda at medinfoUS@takeda.com or by phone at +1-877-825-3327 for more information.

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1). For more information email CRYSTAL-1@centessa.com

An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2. US Only: For more information call Director, Global Clinical Services 888-235-8008 or email: clinicaltrials@alkermes.com Global: For more information call Director, Global Clinical Services 571-599-2702 or email: 571-599-2702

Low sodium oxybate has been approved by the US Food and Drug Association (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts the ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is asleep or awake. Contact Clinical Trial Disclosure & Transparency at ClinicalTrialDisclosure@JazzPharma.com or by phone at 215-832-3750 for more information. OR click study number below to see individual sites and contact information.

The drug being tested in this study is called TAK-861. TAK-861 is being tested to treat people who have narcolepsy type 1 (NT1). This study will look at the safety of TAK-861 along with improvement in narcolepsy symptoms, including excessive daytime sleepiness (EDS) and number of cataplexy episodes. This study was initiated in parallel with the parent phase 2 studies, TAK-861-2001 (NCT05687903) and TAK-861-2002 (NCT05687916), which included participants with NT1 and narcolepsy type 2 (NT2), respectively. This long-term extension (LTE) study enrolled participants with both diagnoses from the two phase 2 studies. As the TAK-861-2002 study did not meet prespecified criteria, all participants with NT2 have been discontinued, and this extension study will only include participants with NT1 who previously completed a parent study. Additional parent studies include all TAK-861 phase 3 studies. The study will enroll up to 500 patients. Participants will be assigned to one of the treatment groups according to the dose assigned to them in their parent study. Similarly, participants who were previously on a placebo dose will also be assigned to one of the treatment groups randomly. All participants in the study will receive TAK-861. Participants with NT1 will receive the following dose from the parent study: TAK-861 Dose 1 TAK-861 Dose 2 This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to approximately 5 years. Participants will make multiple visits to the clinic (with some visits optionally conducted by home health) and will have a follow-up assessment 4 weeks after the last dose of study drug. This is an open label extension that aims to evaluate the safety and tolerability of TAK-861 on participants with type 1 and type 2 narcolepsy from previous parent studies, TAK-861-2001 (NCT05687903) and TAK-861-2002 (NCT05687916). For more information contact 877-825-3327 or email medinfoUS@takeda.com.